JP2012520084A5 - - Google Patents

Download PDF

Info

Publication number
JP2012520084A5
JP2012520084A5 JP2011554266A JP2011554266A JP2012520084A5 JP 2012520084 A5 JP2012520084 A5 JP 2012520084A5 JP 2011554266 A JP2011554266 A JP 2011554266A JP 2011554266 A JP2011554266 A JP 2011554266A JP 2012520084 A5 JP2012520084 A5 JP 2012520084A5
Authority
JP
Japan
Prior art keywords
vector
virus
protein
present
heterologous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011554266A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012520084A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/027262 external-priority patent/WO2010105251A2/en
Publication of JP2012520084A publication Critical patent/JP2012520084A/ja
Publication of JP2012520084A5 publication Critical patent/JP2012520084A5/ja
Withdrawn legal-status Critical Current

Links

JP2011554266A 2009-03-13 2010-03-13 非組み込み型レトロウイルスベクターワクチン Withdrawn JP2012520084A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16028509P 2009-03-13 2009-03-13
US61/160,285 2009-03-13
US16676909P 2009-04-05 2009-04-05
US61/166,769 2009-04-05
US16708809P 2009-04-06 2009-04-06
US61/167,088 2009-04-06
PCT/US2010/027262 WO2010105251A2 (en) 2009-03-13 2010-03-13 Non-integrating retroviral vector vaccines

Publications (2)

Publication Number Publication Date
JP2012520084A JP2012520084A (ja) 2012-09-06
JP2012520084A5 true JP2012520084A5 (enExample) 2013-04-25

Family

ID=42729161

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011554266A Withdrawn JP2012520084A (ja) 2009-03-13 2010-03-13 非組み込み型レトロウイルスベクターワクチン

Country Status (7)

Country Link
US (1) US20120135034A1 (enExample)
EP (1) EP2405945A4 (enExample)
JP (1) JP2012520084A (enExample)
CN (1) CN102438658A (enExample)
CA (1) CA2754603A1 (enExample)
RU (1) RU2012140691A (enExample)
WO (1) WO2010105251A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2667893A2 (en) * 2011-01-27 2013-12-04 Lentigen Corporation Advanced prime and boost vacinne
KR20150029756A (ko) 2011-06-10 2015-03-18 블루버드 바이오, 인코포레이티드. 부신백질이영양증 및 부신척수신경병증을 위한 유전자 요법 벡터
US9713635B2 (en) * 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
WO2013149167A1 (en) * 2012-03-30 2013-10-03 Immune Design Corp. Lentiviral vector particles having improved transduction efficiency for cells expressing dc- sign
ES2745103T3 (es) * 2013-06-15 2020-02-27 Tocagen Inc Partículas inmunosupresivas similares a virus basadas en gammaretrovirus
EP2878674A1 (en) * 2013-11-28 2015-06-03 Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Stable episomes based on non-integrative lentiviral vectors
EP3137100B1 (en) 2014-04-15 2023-12-20 University Of Virginia Patent Foundation Isolated t cell receptors and methods of use therefor
MA41382A (fr) * 2015-03-20 2017-11-28 Univ Temple Édition génique basée sur le système crispr/endonucléase à induction par tat
WO2016154055A1 (en) * 2015-03-20 2016-09-29 Bluebird Bio, Inc. Vector formulations
WO2017066570A1 (en) * 2015-10-15 2017-04-20 The University Of North Carolina At Chapel Hill Methods and compositions for integration-defective lentiviral vectors
EP3426353A4 (en) * 2016-03-09 2020-05-06 The University of Massachusetts USE OF MODIFIED HIV-1 TO GENERATE FULLY HUMAN ANTIBODIES
GB201715052D0 (en) * 2017-09-19 2017-11-01 Oxford Genetics Ltd Vectors
WO2019112921A1 (en) 2017-12-07 2019-06-13 Merck Sharp & Dohme Corp. Formulations of dengue virus vaccine compositions
RU2680703C1 (ru) * 2018-02-13 2019-02-25 Общество с ограниченной ответственностью "Нанолек" Кассета, предназначенная для получения плазмидных векторов, используемых для создания клеток-продуцентов вирусоподобных частиц (ВПЧ) вируса гриппа
RU2680537C1 (ru) * 2018-02-13 2019-02-22 Общество с ограниченной ответственностью "Нанолек" Лентивирусная плазмида (варианты), способ ее получения (варианты), набор праймеров для получения лентивирусного плазмидного вектора (варианты)
RU2681482C1 (ru) * 2018-02-13 2019-03-06 Общество с ограниченной ответственностью "Нанолек" MDCK клетка-продуцент белков вируса гриппа (варианты)
RU2681439C1 (ru) * 2018-02-13 2019-03-06 Общество с ограниченной ответственностью "Нанолек" Вирусоподобная частица вируса гриппа и способ ее получения
WO2020018715A1 (en) 2018-07-17 2020-01-23 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
SG11202104337PA (en) 2018-11-26 2021-05-28 Massachusetts Inst Technology Compositions and methods for immune tolerance
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
CA3189601A1 (en) 2020-07-24 2022-01-27 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
KR20240099340A (ko) * 2021-10-25 2024-06-28 젠비보, 인크. 치료제 또는 백신 전달을 위한 조성물 및 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007659A1 (en) * 1997-04-17 2001-07-12 The University Of California Use of lentiviral vectors for antigen presentation in dendritic cells
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
AU2003273633A1 (en) * 2002-09-26 2004-04-19 K.U.Leuven Research And Development Integrase cofactor
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
EP2055316A1 (en) * 2003-09-09 2009-05-06 VIRxSYS Corporation Lentivirus vector-based approaches for generating an immune response to HIV in humans
WO2005034992A2 (en) * 2003-09-15 2005-04-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv vaccines based on env of multiple clades of hif
FR2872170B1 (fr) * 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
WO2006058231A2 (en) * 2004-11-24 2006-06-01 Nanovector Limited Viral vectors
MX2007010008A (es) * 2005-02-16 2008-01-18 Lentigen Corp Vectores lentivirales y su uso.
GB0526211D0 (en) * 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
PL2020444T3 (pl) * 2007-08-03 2017-10-31 Pasteur Institut Wadliwe nieintegrujące lentiwirusowe wektory przenoszące dla szczepionek

Similar Documents

Publication Publication Date Title
JP2012520084A5 (enExample)
US20120135034A1 (en) Non-Integrating Retroviral Vector Vaccines
CN110958887B (zh) 编码hiv抗原的痘病毒载体及其使用方法
JP2018076363A (ja) レンチウイルス遺伝子導入ベクター及びそれらの医薬品への適用
JP2013027396A (ja) クレードＡ／Ｇ、クレードＢ、およびクレードＣ改変ＨＩＶｅｎｖ、ｇａｇ、およびｐｏｌ遺伝子を発現する組換えＭＶＡウイルス
Di Nunzio et al. HIV-derived vectors for therapy and vaccination against HIV
US20110142880A1 (en) Lentivirus-based immunogenic vectors
CN104039968B (zh) 非b亚型gag蛋白在慢病毒包装中的应用
JP2024502658A (ja) 麻疹－ｈｉｖ又は麻疹－ｈｔｌｖワクチン
CA2825032A1 (en) Advanced prime and boost vaccine
EP1543837A1 (en) Virus-like particle (VLP) as vaccine
RU2697781C2 (ru) Вспомогательный плазмидный лентивирусный экспрессионный вектор для получения высоких титров vpx-содержащих лентивирусных частиц, обеспечивающий эффективное заражение моноцитов и дендритных клеток человека
Wang et al. Polyvalent DNA prime and envelope protein boost HIV‐1 vaccine elicits humoral and cellular responses and controls...
McKenna Characterization and immunogenicity of recombinant rhabdoviral vaccine vectors expressing HIV-1 and SIV envelope proteins
HK1200870B (en) Use of non-subtype b gag proteins for lentiviral packaging